Progyny (NASDAQ:PGNY) Issues Q3 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.500-0.520 for the period, compared to the consensus earnings per share estimate of 0.470. The company issued revenue guidance of $335.0 million-$345.0 million, compared to the consensus revenue estimate of $350.2 million. Progyny also updated its FY 2026 guidance to 2.040-2.100 EPS.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PGNY shares. Barclays reissued an “equal weight” rating and issued a $34.00 price objective (up from $27.00) on shares of Progyny in a report on Tuesday, July 28th. Bank of America increased their target price on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Canaccord Genuity Group increased their price objective on shares of Progyny from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Leerink Partners set a $38.00 target price on shares of Progyny in a report on Wednesday, July 22nd. Finally, KeyCorp boosted their price objective on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.25.

Progyny Price Performance

Shares of PGNY stock traded down $1.16 during mid-day trading on Thursday, hitting $30.21. The stock had a trading volume of 1,863,949 shares, compared to its average volume of 1,465,451. Progyny has a 12-month low of $16.10 and a 12-month high of $33.06. The firm’s 50-day moving average is $28.93 and its two-hundred day moving average is $23.36. The firm has a market capitalization of $2.37 billion, a P/E ratio of 39.23, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business had revenue of $350.51 million for the quarter, compared to the consensus estimate of $348.63 million. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Analysts expect that Progyny will post 1.19 EPS for the current year.

Progyny declared that its Board of Directors has approved a share buyback program on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Insider Transactions at Progyny

In related news, CFO Mark S. Livingston sold 8,275 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $211,012.50. Following the transaction, the chief financial officer directly owned 79,063 shares of the company’s stock, valued at $2,016,106.50. This represents a 9.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the transaction, the director owned 19,772 shares in the company, valued at approximately $521,783.08. This trade represents a 27.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 36,916 shares of company stock worth $939,875. 9.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Progyny

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp raised its stake in shares of Progyny by 1.5% during the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after buying an additional 44,642 shares during the last quarter. Wellington Management Group LLP lifted its stake in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after acquiring an additional 545,431 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after buying an additional 20,533 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Progyny by 12.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock valued at $43,966,000 after acquiring an additional 184,679 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.